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RED CELLS
Red-cell ICAM-4 is a ligand for the monocyte/macrophage integrin
CD11c/CD18: characterization of the binding sites on ICAM-4
Eveliina Ihanus,1 Liisa M. Uotila,1 Anne Toivanen,1 Minna Varis,1 and Carl G. Gahmberg1
1Faculty of Biosciences, Division of Biochemistry, University of Helsinki, Finland
Intercellular adhesion molecule 4 (ICAM-4)
is a unique member of the ICAM family
because of its specific expression on
erythroid cells and ability to interact with
several types of integrins expressed on
blood and endothelial cells. The first re-
ported receptors for ICAM-4 were CD11a/
CD18 and CD11b/CD18. In contrast to
these 2, the cellular ligands and the func-
tional role of the third 2 integrin, CD11c/
CD18, have not been well defined. Here,
we show that ICAM-4 functions as a ligand
for the monocyte/macrophage-specific
CD11c/CD18. Deletion of the individual
immunoglobulin domains of ICAM-4 dem-
onstrated that both its domains contain
binding sites for CD11c/CD18. Analysis of
a panel of ICAM-4 point mutants identi-
fied residues that affected binding to the
integrin. By molecular modeling the im-
portant residues were predicted to clus-
ter in 2 distinct but spatially close regions
of the first domain with an extension to
the second domain spatially distant from
the other residues. We also identified 2
peptides derived from sequences of
ICAM-4 that are capable of modulating
the binding to CD11c/CD18. CD11c/CD18
is expressed on macrophages in spleen
and bone marrow. Inhibition of erythro-
phagocytosis by anti–ICAM-4 and anti-
integrin antibodies suggests a role for
these interactions in removal of senes-
cent red cells. (Blood. 2007;109:802-810)
© 2007 by The American Society of Hematology
Introduction
In general, the major roles of the red blood cells, such as the
transport of oxygen and carbon dioxide throughout the body, have
not been thought to require adhesion of these cells.1 However,
recently it has been demonstrated that erythrocytes express on their
surface proteins known to provide adhesive functions. Many of
these adhesion proteins belong to the immunoglobulin superfamily
of proteins. These molecules may participate in normal red-cell
physiology by mediating cellular interactions during their life cycle
as well as the pathology of human diseases. In bone marrow,
erythroblasts surround central macrophages, forming erythroblas-
tic islands where cell-adhesion events play critical roles in regulat-
ing erythropoiesis. A physiologic interaction between red cells and
leukocytes, platelets, and endothelial cells can also occur during
normal hemostatic conditions (clot formation), pathologic occlu-
sive conditions, and inflammation. Finally, the interaction of
senescent red cells with splenic macrophages is important for
red-cell clearance.1-7
ICAM-4 is a glycoprotein expressed on red blood cells and
erythroid precursor cells concurrently with glycophorin A and Rh
glycoproteins.8-10 The protein was originally described as the LW
blood group antigen (Landsteiner-Wiener), but elucidation of its
primary structure revealed significant similarity to the intercellular
adhesion molecules (ICAMs). It is a 42-kDa glycoprotein com-
posed of 2 immunoglobulin-like domains, a transmembrane part,
and a short cytoplasmic tail.11 The primary cellular counter-
receptors for the ICAMs are the leukocyte-specific 2 integrins,
which consist of 4 heterodimeric glycoproteins with specific 
chains (CD11a, CD11b, CD11c, CD11d) and a common 2 chain
(CD18).12-15 However, ICAM-4 is an unusual ICAM in that it has
recently been found to interact with several types of integrins
expressed on blood and endothelial cells. Like all other members of
the ICAM family,16-20 ICAM-4 binds to the CD11a/CD18 (LFA-1,
L2) integrin expressed on leukocytes.21 ICAM-4 also interacts
with the granulocyte/monocyte-enriched 2 integrin CD11b/CD18
(Mac-1, M2),21 as do ICAM-1 and ICAM-2.22,23 In addition to 2
integrins, ICAM-4 has been shown to bind to v integrins (v1,
v3, and v5) on nonhemopoietic cells, 41 on hemopoietic
cells, and IIb3 on platelets.24-27
Using mutational analysis, we have previously mapped the
binding sites on ICAM-4 for the CD11a/CD18 and CD11b/CD18
integrins.28 The binding site for CD11a/CD18 was shown to be
confined to the first Ig-like domain of ICAM-4, whereas both Ig
domains are involved in CD11b/CD18 binding. Unlike the other
ICAMs, ICAM-4 does not contain the conserved functionally
important glutamate residue in the first domain, which is replaced
by an arginine-52 residue. Mutation of arginine-52 back to
glutamate did not affect CD11a/CD18 binding and even reduced
the interaction with CD11b/CD18. Despite the lack of the con-
served glutamate residue in ICAM-4, we have demonstrated that
the CD11a and CD11b I domains contain an ICAM-4–binding
region.29 These data suggest that the 2 integrin–binding motifs of
ICAM-4 differ from those of other ICAMs.
We and others have previously suggested that ICAM-4 could
mediate red-cell interactions with macrophages.4,21 These interac-
tions are evidently important during the life span of red cells from
erythropoiesis to erythrocyte senescence. CD11c/CD18 is the
major 2 integrin on monocytes/macrophages30; therefore, we
thought that it is important to study its binding characteristics.
Whereas many ligands have been described for the CD11b/CD18
integrin,23,31-34 much less is known about CD11c/CD18. In this
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report we show that ICAM-4 directly binds to the I domain of
CD11c/CD18 and mediates erythrophagocytosis. Furthermore,
using ICAM-4 mutants as well as synthetic peptides of ICAM-4,
we have identified critical sites on ICAM-4 required for its
interaction with CD11c/CD18.
Materials and methods
Antibodies
The monoclonal antibodies (mAbs) used in this study were as follows. The
7E4 and 2E7 mAbs react with the 2 chain,35 TS1/22 (ATCC, Rockville,
MD) recognize the  chain of CD11a/CD18, and MEM170 is specific for
the I domain of CD11b/CD18.36 The anti-CD11c mAbs used included
CBRp150/4G1 and 3.937,38 which were provided by Dr T. Springer
(Harvard Medical School, Boston, MA) and Dr N. Hogg (Cancer Research
UK, London, United Kingdom), respectively, Bly6 (BD PharMingen, San
Diego, CA), BU15 (Serotec, Oxford, United Kingdom), and BL4H4
(Monosan, Hameenlinna, Finland). The mAbs against the first domain of
ICAM-4 (BS46 and BS56) were from Dr H. Sonneborn (Biotest, Dreieich,
Germany).28,39 The mAbs 4C8 and 1A1 against ICAM-4 were from Dr J.-P.
Cartron (Institut National de Transfusion Sanguine, Paris, France). A mouse
IgG1-negative control was purchased from Chemicon (Boronia, Australia)
and a human IgG1 used as a control was from Sigma (St Louis, MO).
FITC-conjugated rabbit anti–mouse F(ab)2 (Dakopatts a/s, Copenhagen,
Denmark) was used for the flow cytometry studies (fluorescence-activated
cell sorting; FACS).
Purification of CD18 integrins and soluble recombinant
Fc proteins
CD11a/CD18, CD11b/CD18, and CD11c/CD18 integrins were purified
from human blood as described previously (Figure S1, available on the
Blood website; see the Supplemental Figure link at the top of the online
article).37,40 cDNA clones encoding the extracellular domains (residues
1-208) of native or mutagenized ICAM-4 and deletion mutants of ICAM-4
containing domain 1 (residues 1-101) or domain 2 (residues 102-208) in the
pIg vector were used to produce soluble Fc-fusion proteins in COS-1
cells.28 The wild-type and Ile314Gly mutant CD11c I domains were
expressed and purified as described.41
Cells and cell lines
Approval was obtained from the Division of Biochemistry, University of
Helsinki institutional review board for these studies. Informed consent was
obtained in accordance with the Declaration of Helsinki.
Blood samples from common LW and Rh phenotypes (ICAM-4–
positive red cells) were obtained from healthy volunteers using heparin as
an anticoagulant.
The wild-type and L929 cells expressing ICAM-1, ICAM-2, or
ICAM-4 have been previously described.29 All the transfectants were grown
in IMDM medium supplemented with 1 mg/mL G418, 10% FBS, 100 U/mL
penicillin, and 100 g/mL streptomycin. The CD11c/CD18-transfected
L929 cell line was provided by Dr Y. van Kooyk (Vrije Universiteit Medical
Center, Amsterdam, The Netherlands) and purified by sorting with a
FACStar Sorter (Becton Dickinson, Immunocytometry Systems, San Jose,
CA), and the G418-resistant cell populations were analyzed with a Becton
Dickinson (Immunocytometry Systems) FACScan flow cytometer. For
FACS analysis macrophages were pretreated with 3% BSA and 20% rabbit
serum, and the stainings were performed in the presence of 1% BSA, 3%
rabbit serum. The COS-1 (ATCC, Manassas, VA) cells were grown in DMEM.
Adhesion assays
Cell adhesion assays were performed as described previously.28,29
For cell-adhesion assays of transfected and wild-type L929 cells 2 mM
MnCl2 was added to the buffers. The biotinylated peptides were immobi-
lized to streptavidin plates (Immobilizer Streptavidin Plate; Nunc, Kam-
strup, Denmark) in 25 mM Tris, pH 8.0, 150 mM NaCl, 2 mM MgCl2, 2
mM CaCl2, 2 mM MnCl2 for 1 hour at room temperature or by overnight
incubation at 4°C.
For the binding study with or without divalent cations, the adhesion
assays were performed with buffers containing 5 mM EDTA, 5 mM EGTA
and 2 mM MgCl2, 2 mM MgCl2 and 2 mM CaCl2, or 2 mM MnCl2.
Solid-phase ELISA assay
Ninety-six–well plates (Greiner, Solingen, Germany) were coated at 4°C
with indicated amounts of CD11c/CD18 in assay buffer (25 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2, 2 mM MnCl2). After
blocking nonspecific sites with 1% HSA for 1 hour at room temperature
(RT) the wells were washed 3 times with assay buffer. The recombinant
ICAM-Fc proteins (25 g/well) were then added to the wells and incubated
for 2 hours at RT. The wells were washed prior to the addition of a
peroxidase-conjugated anti–human Fc mAb (1:1000 dilution; Amersham
Biosciences, Freiburg, Germany) to the wells. After a 1-hour incubation at
37°C, the plates were washed, and the bound proteins were detected with
100 L/well 0.5 mg/mL o-phenylenediamine dihydrochloride added for
10 minutes, stopped by the addition of 50 L 12.5% H2SO4, and read in an
enzyme-linked immunoabsorbent assay (ELISA) reader. For inhibition
experiments, the recombinant soluble Fc fusion proteins or protein-coated
wells were pretreated with different mAbs (50 g/mL).
Synthetic peptides
Peptides synthesized as spots on derivatized cellulose membranes. The
protein sequence of the extracellular part of ICAM-4 was synthesized as 56
membrane-bound peptides 15 amino acids long (SPOTs) with a 3–amino
acid overlap using Abimed Auto-Spot robot ASP 222 (with F-moc
chemistry; Abimed, Langensfeld, Germany).
Soluble peptides. ICAM-4 sequence-derived peptides were synthe-
sized by solid-phase synthesis using F-moc chemistry in an Applied
Biosystems (Weiterstadt, Germany) model 433A automatic peptide synthe-
sizer and purified by reverse-phase chromatography. The sequences of the
peptides were confirmed by MALDI-TOF mass analysis.
The following peptides were synthesized: a 13–amino acid peptide
derived from the Ig-like domain 1 of ICAM-4 (residues 44-56 of
ICAM-4  P-D1; sequence, PQPQNSSLRTPLR), a 13–amino acid peptide
derived from the Ig-like domain 2 of ICAM-4 (residues 161-173 of
ICAM-4  P-D2; sequence, VTLTYEFAAGPRD). Biotinylated versions
of the same peptides were also synthesized to enable possible detection and
immobilization. For the inhibition studies a control peptide (Pcontr1) of 10
residues with the sequence of ELSGRLPWLY was used, as well as a
biotinylated control peptide derived from the cytoplasmic part of ICAM-5
(Pcontr2; sequence, GGGKKGEY).
Peptide-binding assays
For interaction studies, the PepSpot membrane containing the ICAM-4–
derived peptides was blocked o/n at RT with TBST (Tris-buffered saline,
pH 8.0, 0.05% Tween 20) containing 2.5% dried milk, 1.5% BSA, and 5%
sucrose. The membrane was washed 3 times with Tris-buffered saline and
incubated for 1.5 hours at 37°C with purified CD11c/CD18 integrin at a
concentration of 5 g/mL in blocking buffer diluted 3:1 with TBST in the
presence of 1 mM CaCl2, 1 mM MgCl2, and 1 mM MnCl2. After washes the
bound integrin was visualized on X-ray film according to the protocol of
enhanced chemiluminescence (ECL) Western blotting (Amersham Bio-
sciences) using the CD11c/CD18 mAb CBRp150/4G1 (1 g/mL) and
peroxidase-conjugated rabbit antimouse antibody (1:5000 dilution).
Erythrophagocytosis assay
Human buffy coat cells separated by Ficoll-Hypaque centrifugation were
placed in 12-well culture dishes (Greiner) at 3.5 million cells/well. The
adhered monocytes were differentiated to macrophages as described.42 The
phagocytosis experiments were adapted from the method of Bratosin et al.43
First, the macrophage Fc receptors were blocked with heat-inactivated
bovine serum for 10 minutes. Monoclonal anti–ICAM-4 or anti-integrin
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antibodies (40 g/mL) were incubated with macrophages for 20 minutes
before adding 15  106 PKH-26–labeled (cell linker kit; Sigma) red cells.
After 2 hours of incubation at 37°C, macrophages were washed 3 times with
RPMI 1640 medium. Noninternalized red cells were lysed with hypotonic
buffer, and macrophages were detached with lidocaine solution. Cells were
fixed with 70% ethanol and analyzed by flow cytometry. The results were
presented as relative (%) phagocytosis derived from mean values of the
data. Experiments were repeated 3 times in duplicates.
Modeling of ICAM-4
The ICAM-411 (SWISS-PROT accession no. Q14773) model was built on
the structure of ICAM-244 (Protein Data Base code 1ZXQ). Twenty models
were made using the modeling program MODELLER (A. Sali, Department
of Pharmaceutical Sciences, University of California–San Francisco).45
Each model was analyzed first at the overall structural level at which the
models with the highest objective functions were discarded. The objective
function describes the degree of fit of the model to the input structural data
used in its construction, derived by the program MODELLER.45 Then the
orientation of the amino acids in the models were analyzed one amino acid
at a time, giving higher values to those amino acids that have been shown to
be involved in ligand binding.28 In the final model most of the orientations
of the amino acids were shared with the template structure. The objective
function was near the average of the objective functions of all models. The
detailed structural analysis of the ICAM-4 models was made using the
Bodil Molecular Modeling Environment (M. S. Johnson, Structural Bioin-
formatics, Åbo Akademi University, Åbo, Finland).46 The ICAM-4 model
was also validated with PROCHECK (J. M. Thornton, European Bioinfor-
matics Institute, Cambridge, United Kingdom).47 Figure 7A and 7B were
made using the program MOLSCRIPT48 (P. E. Kraulis, Stockholm Univer-
sity, Sweden) and Raster3D (D. J. Bacon and E. A. Merritt, Department of
Biochemistry, University of Washington, Seattle).49,50
Results
Red cells and ICAM transfectants adhere to purified
CD11c/CD18 integrin
In SDS–polyacrylamide gel electrophoresis (PAGE) analysis of the
purified CD11a/CD18, CD11b/CD18, CD11c/CD18, and the wild-
type and mutant CD11c I domain preparations no major impurities
were observed (Figure S1). Both the purified integrins and the
recombinant I domains were tested for correct folding by ELISA
using several anti-integrin antibodies. Red cells readily bound to
coated CD11c/CD18 as well as to the other 2 CD18 integrins
(Figure 1A). The binding to CD11c/CD18 was efficiently inhibited
by monoclonal antibodies to ICAM-4 and CD11c/CD18 (Figure
1B). However, the adhesion was not completely blocked by the
CD11c and ICAM-4 mAbs. There may exist other red-cell
receptors for CD11c/CD18, and the purified immobilized CD11c/
CD18 may not be recognized by the 3.9 antibody with equal
efficiency as cellular integrins. Using purified CD11c/CD18, we
also studied the adhesion of ICAM transfectants29 to coated
CD11c/CD18 (Figure 1C). Their ICAM expression was ascertained
by FACS analysis (Table 1). All the ICAM transfectants adhered to
the coated integrin with similar efficiency (approximately 20% of
the total added cells). Because the expression levels of ICAM-4
and ICAM-2 in L-cell transfectants were about 70% lower than
ICAM-1 transfectants,29 these results suggest that ICAM-4 might
be an even more potent ligand for CD11c/CD18 than ICAM-1. To a
certain extent (10%-20%) the binding efficiencies to ICAMs varied
between different preparations of CD11/CD18 integrins. However,
the same preparations were used in all experiments reported here.
The mAbs to CD11c/CD18 and ICAM-4 clearly inhibited the
binding of ICAM-4 L cells to coated CD11c/CD18 integrin (Figure
1D). The ICAM-4 transfectants also bound to purified CD11c I
domains, and the level of binding was similar both in the wild-type
and the active Ile314Gly mutants41 (not shown).
Soluble ICAM-4 binds to purified CD11c/CD18
Further proof for the specific binding of ICAM-4 to the CD11c/
CD18 integrin was obtained using a cell-free assay (Figure 2). By
performing solid-phase ELISA assays with recombinant soluble
ICAM-4Fc, we showed that ICAM-4 bound to coated purified
CD11a/CD18, CD11b/CD18, and CD11c/CD18 in a dose-
dependent fashion (Figure 2A). High amounts of coated integrin
resulted in decreased binding possibly because of steric hindrance.
Similar effects have been seen before.29 We also found that both
Figure 1. Adhesion of red cells and ICAM-4 transfec-
tants to CD11c/CD18 is mediated by ICAM-4. Adhe-
sion assays were as described in “Materials and meth-
ods.” (A) The binding of erythrocytes to 1 g coated 2
integrins; (B) the inhibitory effect of anti–ICAM-4 (BS46),
anti-CD18 (7E4), and anti-CD11c (3.9) monoclonal anti-
bodies on the adhesion of red cells to purified CD11c/
CD18. (C) Wells were coated with 1 g purified CD11c/
CD18, and the adhesion of parental L cells and different
ICAM L-cell transfectants was measured. (D) The effect
of antibodies on binding of ICAM-4 L-cell transfectants to
1 g coated CD11c/CD18 was studied. The data in
panels A and C are presented as a percentage of
attached cells (amount of bound cells divided by input of
cells). The results in panels B and D are expressed as a
relative percentage of bound cells, where 100% is calcu-
lated from the total number of cells bound to the CD11c/
CD18 in the absence of pretreatment with MAbs. The
significance was determined by unpaired Student t test.
Controls included unrelated mouse IgG antibody and
wells with coated control protein (GPA) or without coated
protein (BSA only). Background binding of cells to GPA or
BSA was subtracted. The experiments were repeated 3
times with similar results. Data are expressed as mean
SD, and statistical significances are shown, ***P  .005.
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CD11c/CD18-specific mAbs (3.9 and BU15) and anti-CD18 anti-
body 7E4 partially but significantly inhibited the binding, whereas
the 1A1 (anti–ICAM-4) blocked more efficiently (Figure 2B).
Integrin transfectants adhere to ICAM-4
The surface expression of 2 integrins on CD11c/CD18 transfec-
tants was studied by FACS (Table 1). As shown in Figure 3A the
coated chimeric ICAM-4Fc protein supported the adhesion of
CD11c/CD18 transfectants. Some background binding of untrans-
fected L cells was observed, indicating additional interactions. To
check the specificity of the interaction, we studied the effects of
mAbs on the adhesion of transfectants to ICAM-4Fc (Figure 3B).
Monoclonal antibodies against either the  or  chain inhibited the
binding of CD11c/CD18 transfectants approximately by 50% to
85%, whereas the anti–ICAM-4 mAbs blocked the binding effi-
ciently down to background levels. To obtain further evidence of
specificity, we investigated the divalent cation requirements of the
CD11c/CD18 transfectant binding to ICAM-4Fc (Figure 3C). In
the absence of cations, the adhesion was efficiently but not totally
abolished. As can be seen in Figure 3C, MgCl2 alone or in
combination with CaCl2 was not sufficient to support the maximal
binding of CD11c/CD18 L cells to ICAM-4Fc. Indeed, the
presence of Mn2	 seems to be required for high-affinity binding of
CD11c/CD18 transfectants to ICAM-4. Interestingly, the binding
was efficiently inhibited by the soluble active mutant of CD11c I
domain (Figure 3D).
CD11c/CD18 integrin binding sites on ICAM-4
To establish which ICAM-4 Ig domains contain CD11c/CD18
binding sites, ICAM-4 deletion mutants lacking either domain D1
or D2 were tested in cell-adhesion assays (Figure 4A). Neither
domain alone was sufficient for the maximal binding of CD11c/
CD18 transfectants. However, both domain deletion mutants
retained partial binding capacity. As expected, the anti–ICAM-4
mAb, 1A1, the epitopes of which reside within domain D1, affected
only the binding to the wild-type ICAM-4Fc and the deletion
mutant carrying domain D1. The I domain–specific anti-CD11c
mAb, 3.9, inhibited CD11c/CD18 transfectant binding partially to
wild-type ICAM-4 and only slightly to the mutant lacking D1.
Instead, the adhesion to the mutant lacking domain D2 was almost
totally abolished by 3.9.
To define the binding sites of CD11c/CD18 in ICAM-4 in more
detail, we tested 32 ICAM-4Fc mutant proteins.28 The residues
targeted for mutation were all expected to be surface exposed,
being able to participate in molecular interactions with counter-
receptors. The mutant proteins were tested for correct folding by
ELISA with the anti–ICAM-4 mAb, 1A1. This mAb also reacted
with the Trp19Ala mutant not recognized by the BS mAbs in our
previous report, indicating partially correct folding.
As shown in Figure 4B, 4 single point mutations caused a
reduction in cell adhesion by 38% or greater. However, when the
control binding (29%) is taken into account, the adhesion was
reduced by 54% or greater. Three of these are located within
domain D1 on the A strand at position Trp19, on the C strand at
position Arg52, and in the E to F loop at position Trp77. One of
these 4 mutations localized to D2, on the strand E at position
Glu166. The Arg52Ala mutation almost completely eliminated
binding. In addition to these 4 ICAM-4 mutants, the adhesion to
mutants at positions Thr91, Trp93, and Arg 97 reduced adhesion by
25% to 30% (background not subtracted). When the Arg residues at
positions 52 and 97 were mutated to opposite charge (Glu), the
Figure 2. Soluble ICAM-4Fc binds specifically to immobilized purified CD11c/CD18 in a solid-phase assay. (A) Dose-dependent binding of recombinant ICAM-4Fc to
coated integrins. ICAM-4Fc 	 CD11a/CD18 (f), ICAM-4Fc 	 CD11b/CD18 (E), ICAM-4Fc 	 CD11c/CD18 (Œ). Background binding of control protein (human IgG1) was
subtracted. (B) The effect of monoclonal antibodies on binding of soluble ICAM-4Fc to 0.4 g coated CD11c/CD18 in a solid-phase assay is shown. The ICAM-4Fc binding to
CD11c/CD18 was examined in the presence of mAbs (50 g/mL) against the ICAM-4 (1A1), CD18 (7E4), and CD11c (3.9, BU15). Data shown are from 1 representative
experiment of 3. Standard deviations and statistical significances are shown; ***P  .005, **P .05. The significances were determined by unpaired Student t test.
Table 1. Antigen profiles of the L cells and macrophages determined by flow cytometry
Antigen
Wt L
cells
ICAM-1 L
cells
ICAM-2 L
cells
ICAM-4 L
cells
CD11c L
cells Macrophages
Isotype control Ig 2.3  0.2 3.2  1.1 3.2  0.7 3.4  0.5 4.0  0.9 11.7  4.9
ICAM-1 3.4  1.3 98.6  12.1 6.3  9.9 4.2  0.3 — —
ICAM-2 2.7  0.4 3.4  1.4 25.7  0.7 3.4  0.4 — —
ICAM-4 2.7  0.5 4.4  1.7 3.0  0.7 29.0  3.8 — —
CD11a 2.1  0.1 — — — 5.2  1.9 69.5  35.5
CD11b 2.3  0.1 — — — 3.9  1.1 95.6  19.5
CD11c 2.1  0.1 — — — 35.9  14.8 74.9  34.8
CD18 2.4  0.3 — — — 28.2  15.6 78.9  56.8
The values given are the mean fluorescence intensities  SEM of 3 flow cytometric experiments. Cultured macrophages were from different healthy donors.
— indicates not applicable.
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effect on cell adhesion was weaker than observed with substitution
by an apolar amino acid (Ala), indicating that charge is needed at
these positions. Furthermore, replacement of Trp at position 77 by
Phe caused a severe reduction of CD11c/CD18 L-cell adhesion,
whereas substitution by Ala had a minor effect. However, for the
double mutants Arg52Glu/Thr91Gln and Trp77Ala/Glu151Ala a
40% and 30% reduction in cell adhesion was noted, respectively,
confirming the importance of ICAM-4 residues Arg52, Thr91, and
Trp77 in CD11c/CD18 binding. According to these data, of the 7
residues critical for ICAM-4 interaction with CD11c/CD18 inte-
grin, 6 are spatially close, spanning the interface between the
ABED and CFG faces of domain D1 with an extension of one
important residue far from the others in the domain D2 (Figure 5A).
ICAM-4–derived peptides interact with CD11c/CD18 and inhibit
cell adhesion
Using a PepSpot assay, we were able to identify 2 peptide regions
derived from ICAM-4 which selectively bound to soluble purified
CD11c/CD18 integrin. CD11c/CD18 reacted with 5 overlapping
peptides spanning the ICAM-4 sequence of amino acids 39 to 65
located in domain D1 and with 3 peptides spanning the sequence of
amino acids 159 to 179 located in domain D2 (Figure 6). Consistent
with the mutation results the peptide region from domain D1
includes the important Arg52 (see Figure 4). Furthermore, the only
critical amino acid mutation localized to D2 at position Glu166 was
included in the selected peptide sequences from D2. According to
these results, 2 peptides were chosen for further analysis in
cell-adhesion assays: P-D1 (PQPQNSSLRTPLR) covering the C
strand and parts of the loops at both ends of the C strand in the
domain 1 and P-D2 (VTLTYEFAAGPRD) derived from the
domain 2 and covering the E strand and part of the loop connecting
the E strand to F strand (Figure 5B). Two available control
peptides, Pcontr1 (ELSGRLPWLY) and Pcontr2 (biotinylated
GGGKKGEY), were used in the cell-adhesion assays, but in the
PepSpot assays the negative and flanking peptides also acted
as controls.
The immobilized P-D2 peptide supported binding of CD11c/
CD18 transfectants efficiently, whereas the P-D1 peptide supported
Figure 3. CD11c/CD18 transfectants show specific
cation-dependent binding to coated ICAM-4Fc. (A)
The adhesion of parental L cells and CD11c/CD18
transfectants to ICAM-4Fc and human IgG proteins
coated on plastic wells. CD11c/CD18 L cells	 ICAM-4Fc
(f), parental L cells 	 ICAM-4Fc (Œ), CD11c/CD18 L
cells 	 human IgG (E), parental L cells 	 human IgG
(). (B) The effects of anti–ICAM-4, anti-CD18, and
anti-CD11c mAbs on adhesion of CD11c/CD18 transfec-
tants to 0.5 g purified ICAM-4Fc fusion protein. Controls
included wells with binding of wild-type L cells (not
shown) and the effect of control antibody (anti-CD11a
mAb). (C) The binding of transfectants to ICAM-4Fc in
the absence or presence of divalent cations. (D) The
binding of CD11c/CD18 transfectants to coated ICAM-
4Fc in the presence of indicated concentrations of soluble
wild-type CD11c I domain (f) and the active mutant I
domain (E). In panels A and B the results are shown as
the percentage of input cells bound  SD. In panels C
and D the results are expressed as a relative percentage
of bound cells, where 100% is given as the number of
cells bound to the ICAM-4Fc in the presence of divalent
cations (C) or in the absence of soluble I domain (D).
Background binding of cells to HSA was subtracted. The
experiments were repeated 3 to 5 times with similar
results. Standard deviations and statistical significances
are shown; ***P  .001, **P  .01.
Figure 4. Effects of domain deletion mutations and amino acid substitutions on ICAM-4 binding to CD11c/CD18 transfectants. Adhesion of CD11c/CD18-expressing L
cells to plastic-coated native and mutated ICAM-4Fc (0.5 g/well). Results are shown as the percentage of CD11c/CD18 transfectant-cell binding relative to native ICAM-4Fc
(100%). (A) The binding of CD11c/CD18 transfectants to ICAM-4 domain deletion mutants in the absence or the presence of mAbs 1A1 (anti–ICAM-4) or 3.9 (anti-CD11c).
Controls included wells with binding of wild-type L cells and the effect of control antibody (not shown). Background binding of cells to HSA was subtracted. Panel B shows the
adhesion of CD11c/CD18 transfectants to a panel of ICAM-4 mutants. The mean SD from 3 experiments is shown.
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adhesion only weakly. The binding profiles of the 2 peptides were
clearly different as well (Figure 6B). Both peptides inhibited the
interaction between ICAM-4 and CD11c/CD18. However, the
P-D2 peptide was a significantly more effective blocker of the
CD11c/CD18 L-cell binding. Figure 6C shows that the inhibition of
CD11c/CD18 transfectant adhesion to ICAM-4Fc by the P-D2
peptide was concentration dependent, and 65% inhibition was
obtained with a peptide concentration of 500 M. The P-D1
peptide was less active. The blocking activity was reduced with
higher P-D1 amounts. When the peptides were tested together,
there was an additional inhibition of binding.
Erythrophagocytosis is mediated by ICAM-4/2
integrin interaction
To find a possible physiologic role of the ICAM-4/2 integrin
interaction we studied erythrophagocytosis. The expression of 2
integrins on cultured, monocyte-derived macrophages was verified
by FACS (Table 1). The uptake of PKH-26–labeled red cells by
human macrophages was effectively inhibited by antibodies against
ICAM-4 and 2 integrins. Figure 7 shows that these mAbs reduced
the phagocytosis of red cells by 50% or more. Greater than 60%
inhibition was obtained in the presence of the 3.9 CD11c mAb.
Figure 5. Critical residues of ICAM-4 involved in interaction with 2 integrins and location of ICAM-4 peptides that mediate adhesion to CD11c/CD18 integrin. (A)
Three-dimensional representation of an ICAM-4 model constructed on the basis of ICAM-2 structure. Amino acids are designated by 3-letter codes and residue numbers. The
solvent-accessible surfaces of ICAM-4 residues that when mutated cause a decrease in adhesion to CD11a/CD18 (left), CD11b/CD18 (middle), and CD11c/CD18 (right) are
colored (Trp, orange; Arg, cyan; Leu, green; Thr, magenta; Glu, red). (B) A ribbon diagram of ICAM-4 displayed in 3 orientations 120 degrees to one another. The strands of the
antiparallel  sheets are labeled by capital letters. The locations of the ICAM-4 peptides are colored: P-D1 (PQPQNSSLRTPLR), residues 44 to 56 (cyan); P-D2
(VTLTYEFAAGPRD), residues 161 to 173 (red). Side chains of the 2 peptide residues found to be involved in CD11c/CD18 binding by mutagenesis studies are shown as ball
and stick.
Figure 6. CD11c/CD18 binds selectively to peptides derived from the ICAM-4 sequence. (A) A total of 56 overlapping synthetic peptides 15 amino acid-long that
corresponded to the protein sequence of the extracellular part of ICAM-4 were synthesized as immobilized spots on a cellulose membrane. The reactivities of the peptides with
purified CD11c/CD18 integrin were tested. The CD11c/CD18 mAb CBRp150/4G and peroxidase-conjugated rabbit antimouse antibody were used to detect bound
CD11c/CD18 integrin. The figure shows the reactivity of the overlapping peptides selected with the soluble CD11c/CD18 integrin. Negative control was carried out in the
absence of the integrin. According to these results 2 peptides were chosen for solid-phase synthesis: P-D1 derived from the ICAM-4 Ig-like domain 1 and P-D2 derived from the
domain 2. Both of the peptides included an amino acid shown to be involved in adhesion to CD11c/CD18 according to our mutational studies (see Figure 4). (B) The adhesion of
the CD11c/CD18 transfectants to biotinylated versions of the selected ICAM-4 peptides and a control peptide (Pcontr2) captured by streptavidin microplates. Indicated
amounts of the peptides were coated per well, and the cell adhesion was performed as described in “Materials and methods.” Sequences of the synthesized ICAM-4–derived
peptides and the peptides used as control are listed in the figure. (C) The effects of the defined ICAM-4 peptides and the control peptide on adhesion of the CD11c/CD18
transfectants to coated ICAM-4Fc are shown. The cells were pretreated or not with the control peptide (Pcontr1), P-D1, P-D2 or the P-D1 and P-D2 peptides together at
different final concentrations. A representative binding experiment with results expressed as the percentage of input cells bound are shown. Control peptides (f), P-D2 (Œ),
P-D1 (E), P-D1	 P-D2 ().
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Discussion
ICAM-4 is remarkable because of its ability to bind several
members of integrin subclasses. These include the v integrins
(v1, v3, and v5), 41 and IIb3,24-26 in addition to
CD11a/CD18 and CD11b/CD18.21 The binding sites for all the
ICAM-4 receptor integrins, except for CD11a/CD18, comprise
residues on both Ig-like domains of ICAM-4. The regions of
ICAM-4 identified as 2 and 3 integrin interaction sites appear
clearly distinct, although they all share W77. The ICAM-4 amino
acids predicted to be critical for binding to v1 and v5 are
located in close proximity to those needed for 2 integrin interac-
tion. However, R97 is the only residue that is shared between the 2
sites.25,26,28,51 The ability of ICAM-4 to interact selectively with
several different integrin receptors suggests multiple functions for
ICAM-4 in red-cell physiology and pathology.27
The CD11c/CD18 (x2) integrin is most homologous to the
CD11b/CD18 and CD11d/CD18 integrins with 60% to 66% amino
acid identity, whereas it is only 37% identical to CD11a/CD18.52-54
CD11c/CD18 plays an important role in phagocytosis, chemotaxis,
and regulation of the immune response.12,13 Little is known about
the cellular ligands of CD11c/CD18, but the ligands appear to
overlap in part with those of CD11b/CD18. In addition to several
soluble and matrix ligands, the only reported cellular ligands for
CD11c/CD18 are ICAM-137,55 and Thy-1.56 A recent study shows
that the binding site of CD11c/CD18 on ICAM-1 resides on
domain D4,57 and another report suggested that negatively charged
residues in structurally decayed proteins serve as a pattern recogni-
tion motif for CD11c/CD18.58 Preliminary experiments indicated
that CD11c/CD18 in THP-1 cells binds to purified ICAM-4, but we
failed to see binding to red cells.21 This could be due to low affinity
of CD11c/CD18, but now we have used an antibody, which allows
purification in a functionally active form.37
In this study we have convincingly demonstrated that red-cell
ICAM-4 binds to CD11c/CD18: (1) red cells and ICAM-4 L-cell
transfectants adhered to immobilized purified CD11c/CD18; (2)
the specificity was confirmed by the ability of antibodies against
CD11c/CD18 and ICAM-4 to block the adhesion;, (3) with purified
CD11c/CD18 and ICAM-4 a direct binding was observed; (4)
adhesion of the CD11c/CD18 transfectants to recombinant-coated
ICAM-4Fc was inhibited by soluble I domain, the antibodies
against ICAM-4, and the  and  subunits of the CD11c/CD18; (5)
ICAM-4 deletion mutants lacking either domain D1 or D2 showed
lower binding to CD11c/CD18; (6) the panel of point mutants
studied resulted in the identification of 7 residues of ICAM-4
important for binding to CD11c/CD18. ICAM-4 residues in
domain D1 (Trp19, Arg52, Trp77, Thr91, Trp93, and Arg97) have
previously been shown to be involved in binding to CD11b/CD18
as well.
Figure 5 shows a model of the external part of the ICAM-4
molecule, with critical amino acids marked defining distinct but
overlapping 2 integrin binding footprints on ICAM-4. As ex-
pected, our model is consistent with the one published by Hermand
et al28 because these both have the same template structure.
Furthermore, the amino acids that were reported to reside on the
surface of the protein51 are on the surface in our model as well. D1
residues showing the greatest specific effect on CD11c/CD18
binding, and which may be central in the binding site, are Arg52 at
the bottom of strand C, Trp19 at the top of strand A, and Trp77 on
the E to F loop. Trp19, Arg52, Thr91, and Trp93 lie approximately
in the middle of domain D1.
Previous and current results show that both Ig-like domains of
ICAM-4 are involved in binding to CD11b/CD18 and CD11c/
CD18. However, the vital ICAM-4 residues in domain D2 mediat-
ing adhesion to the 2 integrins are different. Mutation of Glu166 at
the bottom of strand E in D2 reduced binding to CD11c/CD18,
whereas the recognition site for CD11b/CD18 is located in the C to
E loop of D2 far from the CD11c/CD18 binding site. The model of
ICAM-4 shows that the location of the Glu166 is spatially distant
from the rest of the integrin-binding footprint. This could indicate
that the integrin molecules interact with a large surface area of the
ICAM-4 molecule. It is interesting to note that in all other ICAMs
there is a glutamic acid residue in the first domains, which are
needed for adhesion, but in ICAM-4 this is replaced by Arg52.
Glu166 may substitute for this. The binding of the CD11b/CD18
and CD11c/CD18 integrins to additional sites present on domain
D2 of ICAM-4 is consistent with the stronger binding to ICAM-4
observed for these 2 2 integrins as compared with CD11a/CD18.
The I domain–specific anti-CD11c mAb, 3.9, efficiently blocked
the binding to the D2 deletion mutant but only slightly to the D1
deletion mutant. These data suggest that the I domain mainly
binds to the D1 of ICAM-4, but they also indicate that multiple
regions of the CD11c/CD18 could be involved in the interaction
with ICAM-4.
Our results with synthetic peptides provided additional support
for the role of ICAM-4 residues identified by site-directed mutagen-
esis. Using PepSpot analysis, we found 2 peptides derived from
ICAM-4 reacting with CD11c/CD18. Both peptides included
amino acids (Arg52 in D1 and Glu166 in D2) shown to be needed
for CD11c/CD18 binding. The peptide binding and inhibition data
are consistent with those of our mutational results and support the
finding that both ICAM-4 domains are involved in binding to
CD11c/CD18. The 2 peptides and the critical residues are exposed
at the surface of the ICAM-4 molecule being available for
interactions (Figure 5).
The role of ICAM-4 in red-cell physiology has remained poorly
understood. CD11c/CD18 is expressed on macrophages30 (Table
1), and we report here that erythrophagocytosis was prevented by
the inhibition of ICAM-4-2 integrin binding, indicating that this
interaction may be important in removal of erythrocytes from the
circulation by splenic macrophages. Interestingly, in a recent report
erythroblastic island formation was shown to decrease in ICAM-4–
null mice, and the interactions between erythroblast ICAM-4 and
macrophage v integrin were reported to be critical for island
Figure 7. Phagocytosis of red cells by macrophages is inhibited by 2 integrin
and ICAM-4 antibodies. (A) Effect of mAbs against the CD11a (TS1/22), CD11b
(MEM170), CD11c (3.9), CD18 (2E7), and ICAM-4 (1A1) on erythrophagocytosis.
The results are presented as relative phagocytosis derived from mean values of the
data; ***P  .001, **P  .01.
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integrity.59 Thus, ICAM-4 seems to be important for red-cell
development and turnover. Furthermore, secreted isoforms of
ICAM-4 may be important regulators of these molecular
interactions.11,60
Although it has been commonly accepted that normal red cells
are fairly nonadhesive during coagulation and thrombosis, increas-
ing evidence shows that red cells are in fact able to form adhesive
interactions during these physiologic processes. The ICAM-4/
integrin interactions could be important during hemostasis where,
in the developing thrombus, erythrocytes interact with activated
neutrophils and monocytes. This possibility is supported by the fact
that under low flow conditions adhesion of red cells to activated
neutrophils involves interaction of ICAM-4 with CD11b/CD18.61
The finding that ICAM-4 binds to the platelet integrin IIb3
indicates that this interaction may be involved in platelet-
erythrocyte aggregate formation during coagulation.26 Interest-
ingly, recent data indicate that during the pathogenesis of sickle
red-cell vasoocclusion, adherent leukocytes bind not only to the
inflamed endothelium but also to the erythrocytes.62 Furthermore, a
recent report shows that activated ICAM-4 mediates binding of the
sickle red cells to endothelial v3 integrin.63 These findings
indicate that drugs targeting ICAM-4-integrin interactions would
be of great therapeutic value. Our results with synthetic peptides
suggest that modulation of these interactions is possible.
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